What is the appropriate treatment for angina in a male patient with HIV, considering potential drug interactions with his antiretroviral therapy?

Treatment for Angina in a Man with HIV

Treat angina in HIV patients with standard antianginal therapy (beta-blockers or calcium channel blockers as first-line), but you must carefully manage statin interactions with antiretroviral therapy and avoid boosted protease inhibitors when possible due to cardiovascular and drug interaction concerns 1, 2.

Standard Antianginal Therapy Applies

The core treatment approach for angina remains the same regardless of HIV status:

• Beta-blockers or calcium channel blockers are first-line antianginal agents for symptom control 1
• Short-acting nitrates for acute symptom relief
• Long-acting nitrates, ivabradine, or ranolazine as second-line options if needed

For vasospastic angina specifically (if suspected based on rest angina with ST-segment changes that resolve with nitrates):

• Calcium channel blockers are the definitive treatment to control symptoms and prevent potentially fatal complications 1

Critical HIV-Specific Considerations

Statin Management (Most Important Drug Interaction)

Attention to interaction between antiretroviral treatment and statins is mandatory 1. This is the single most important drug interaction to manage:

• Avoid simvastatin and lovastatin entirely with most antiretrovirals (especially boosted protease inhibitors and certain integrase inhibitors)
• Preferred statins: atorvastatin (start low dose, 10-20mg) or rosuvastatin (5-10mg), with careful dose titration
• Pitavastatin has minimal drug interactions and may be ideal if available
• Monitor closely for myopathy symptoms (muscle pain, weakness) and check CK if symptomatic

Antiretroviral Regimen Optimization

If the patient is on a boosted protease inhibitor (ritonavir- or cobicistat-boosted regimens):

• Consider switching to dolutegravir or bictegravir-based regimens if virologically suppressed 2
• These newer integrase inhibitors have:
  • Fewer cardiovascular risk factors
  • Reduced drug-drug interactions with cardiovascular medications
  • High barrier to resistance
  • Better lipid profiles compared to protease inhibitors

This switch is particularly advantageous for patients with cardiovascular disease or hyperlipidemia that may be exacerbated by boosted protease inhibitors 2.

Antiplatelet Therapy

• Low-dose aspirin (75-100mg daily) is recommended as a disease-modifying agent for chronic coronary syndrome 1
• No specific contraindications with modern antiretrovirals
• Standard dual antiplatelet therapy if revascularization is performed

Additional Cardiovascular Risk Management

Older adults (≥75 years) require particular attention to:

• Drug side effects and intolerance
• Drug-drug interactions (especially critical in HIV patients)
• Overdosing risks
• Procedural complications 1

Practical Algorithm

1. Initiate standard antianginal therapy: Beta-blocker or calcium channel blocker
2. Review current antiretroviral regimen: If on boosted protease inhibitor, coordinate with HIV specialist to switch to dolutegravir/bictegravir-based regimen
3. Start statin therapy: Use atorvastatin 10-20mg or rosuvastatin 5-10mg (avoid simvastatin/lovastatin completely)
4. Add low-dose aspirin: 75-100mg daily
5. Use drug interaction checker: Liverpool Drug Interaction Checker is specifically validated for HIV medications 3
6. Monitor closely: More frequent follow-up initially to detect any unanticipated toxicities or interactions

Common Pitfalls to Avoid

• Never use simvastatin or lovastatin with antiretrovirals—this is the most dangerous interaction
• Don't assume all statins are equivalent—dose adjustments are critical based on specific antiretroviral agents
• Don't overlook the opportunity to optimize ART—switching from protease inhibitors can reduce both cardiovascular risk and drug interactions 2
• Don't forget bleeding risk assessment if considering revascularization, as HIV patients may have higher recurrence rates 4

When to Refer for Invasive Assessment

If symptoms persist despite optimal medical therapy:

• Stress imaging for risk stratification is recommended 1
• Consider invasive coronary functional testing if ANOCA/INOCA suspected (angina with normal or non-obstructive coronary arteries) 1
• HIV patients may have more complex coronary disease with higher SYNTAX scores 4, warranting careful evaluation

The key to success is coordinated care between cardiology and infectious disease specialists, using validated drug interaction tools, and recognizing that modern integrase inhibitor-based ART regimens offer significant advantages for cardiovascular safety 2, 3.